Spots Global Cancer Trial Database for azacitidine injection
Every month we try and update this database with for azacitidine injection cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). | NCT06078306 | B Acute Lymphob... Ph-Negative ALL High Risk Acute... | Azacitidine Inj... Venetoclax CD19CD22 CAR-T | 18 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | NCT03843528 | Acute Myeloid L... Myelodysplastic... Mixed Phenotype... Juvenile Myelom... | Vorinostat Azacitidine Inj... | 1 Year - 21 Years | Johns Hopkins All Children's Hospital | |
| A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score | NCT06279338 | Myelodysplastic... | Azacitidine Inj... | 18 Years - | Wuhan Union Hospital, China | |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | NCT03843528 | Acute Myeloid L... Myelodysplastic... Mixed Phenotype... Juvenile Myelom... | Vorinostat Azacitidine Inj... | 1 Year - 21 Years | Johns Hopkins All Children's Hospital | |
| Pharmacokinetics, Tolerability and Safety of NEX-18a | NCT05048498 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | NEX-18a injecti... Azacitidine Inj... | 18 Years - | Nanexa AB | |
| CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). | NCT06078306 | B Acute Lymphob... Ph-Negative ALL High Risk Acute... | Azacitidine Inj... Venetoclax CD19CD22 CAR-T | 18 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | NCT05559008 | Peripheral T Ce... | Azacitidine Inj... Dasatinib Linperlisib Tucidinostat SHR2554 Camrelizumab Apatinib | 18 Years - | Ruijin Hospital | |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] | NCT06150040 | Acute Myeloid L... | NP137 Azacitidine Inj... Venetoclax | 65 Years - | Centre Leon Berard | |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | NCT05559008 | Peripheral T Ce... | Azacitidine Inj... Dasatinib Linperlisib Tucidinostat SHR2554 Camrelizumab Apatinib | 18 Years - | Ruijin Hospital | |
| A Pivotal Phase 3 Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia | NCT06389292 | Acute Myeloid L... | Lisaftoclax (AP... Placebo Azacitidine Inj... | 18 Years - | Ascentage Pharma Group Inc. | |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] | NCT06150040 | Acute Myeloid L... | NP137 Azacitidine Inj... Venetoclax | 65 Years - | Centre Leon Berard | |
| A Pivotal Phase 3 Study of APG-2575 (Lisaftoclax) Combined With Azacytidine in the Treatment of Acute Myeloid Leukemia | NCT06389292 | Acute Myeloid L... | Lisaftoclax (AP... Placebo Azacitidine Inj... | 18 Years - | Ascentage Pharma Group Inc. | |
| A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score | NCT06279338 | Myelodysplastic... | Azacitidine Inj... | 18 Years - | Wuhan Union Hospital, China | |
| A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score | NCT06279338 | Myelodysplastic... | Azacitidine Inj... | 18 Years - | Wuhan Union Hospital, China | |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] | NCT06150040 | Acute Myeloid L... | NP137 Azacitidine Inj... Venetoclax | 65 Years - | Centre Leon Berard |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
